These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 26311727)

  • 1. Does molecular monitoring matter in early-stage breast cancer?
    Sundaresan TK; Haber DA
    Sci Transl Med; 2015 Aug; 7(302):302fs35. PubMed ID: 26311727
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer.
    Garcia-Murillas I; Schiavon G; Weigelt B; Ng C; Hrebien S; Cutts RJ; Cheang M; Osin P; Nerurkar A; Kozarewa I; Garrido JA; Dowsett M; Reis-Filho JS; Smith IE; Turner NC
    Sci Transl Med; 2015 Aug; 7(302):302ra133. PubMed ID: 26311728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantification of LINE1 in circulating DNA as a molecular biomarker of breast cancer.
    Sunami E; Vu AT; Nguyen SL; Giuliano AE; Hoon DS
    Ann N Y Acad Sci; 2008 Aug; 1137():171-4. PubMed ID: 18837943
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detecting Plasma Tumor DNA in Early-Stage Breast Cancer-Letter.
    Kodahl AR; Pallisgaard N; Jylling AM; Cold S; Knoop AS; Ditzel HJ
    Clin Cancer Res; 2015 Aug; 21(15):3569. PubMed ID: 26240292
    [No Abstract]   [Full Text] [Related]  

  • 5. Detecting Plasma Tumor DNA in Early-Stage Breast Cancer--Reply.
    Beaver JA; Park BH
    Clin Cancer Res; 2015 Aug; 21(15):3570. PubMed ID: 26240293
    [No Abstract]   [Full Text] [Related]  

  • 6. Minimal residual disease in breast cancer: in blood veritas.
    Siravegna G; Bardelli A
    Clin Cancer Res; 2014 May; 20(10):2505-7. PubMed ID: 24658155
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liquid Biopsies for Monitoring Temporal Genomic Heterogeneity in Breast and Colon Cancers.
    Venesio T; Siravegna G; Bardelli A; Sapino A
    Pathobiology; 2018; 85(1-2):146-154. PubMed ID: 28614831
    [TBL] [Abstract][Full Text] [Related]  

  • 8. p53 mutation in plasma DNA and its prognostic value in breast cancer patients.
    Shao ZM; Wu J; Shen ZZ; Nguyen M
    Clin Cancer Res; 2001 Aug; 7(8):2222-7. PubMed ID: 11489795
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of breast cancer after ovarian cancer on mortality for BRCA mutation carriers.
    Liede A; Sun P; Narod S
    JAMA Surg; 2015 May; 150(5):490-1. PubMed ID: 25807333
    [No Abstract]   [Full Text] [Related]  

  • 10. Effect of breast cancer after ovarian cancer on mortality for BRCA mutation carriers--reply.
    Gangi A; Baramparas G; Amersi FF
    JAMA Surg; 2015 May; 150(5):491-2. PubMed ID: 25807476
    [No Abstract]   [Full Text] [Related]  

  • 11. Breast cancer: Tracking ctDNA to evaluate relapse risk.
    Romero D
    Nat Rev Clin Oncol; 2015 Nov; 12(11):624. PubMed ID: 26370605
    [No Abstract]   [Full Text] [Related]  

  • 12. Loss of heterozygosity in serial plasma DNA samples during follow-up of women with breast cancer.
    Wang Q; Larson PS; Schlechter BL; Zahid N; Finnemore E; de las Morenas A; Blanchard RA; Rosenberg CL
    Int J Cancer; 2003 Oct; 106(6):923-9. PubMed ID: 12918071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic Accuracy of PIK3CA Mutation Detection by Circulating Free DNA in Breast Cancer: A Meta-Analysis of Diagnostic Test Accuracy.
    Zhou Y; Wang C; Zhu H; Lin Y; Pan B; Zhang X; Huang X; Xu Q; Xu Y; Sun Q
    PLoS One; 2016; 11(6):e0158143. PubMed ID: 27336598
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cell-free DNA as a molecular tool for monitoring disease progression and response to therapy in breast cancer patients.
    Liang DH; Ensor JE; Liu ZB; Patel A; Patel TA; Chang JC; Rodriguez AA
    Breast Cancer Res Treat; 2016 Jan; 155(1):139-49. PubMed ID: 26667234
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating DNA as biomarker in breast cancer.
    Schwarzenbach H; Pantel K
    Breast Cancer Res; 2015 Oct; 17(1):136. PubMed ID: 26453190
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 55-year-old woman with menopausal symptoms and a family history of breast cancer.
    Mallin EA; Pavlicek W
    Mayo Clin Proc; 2008 Apr; 83(4):485-8. PubMed ID: 18380995
    [No Abstract]   [Full Text] [Related]  

  • 17. Sequencing efforts help to refine the molecular classification of breast cancer.
    Konecny GE
    Curr Opin Obstet Gynecol; 2014 Feb; 26(1):18-20. PubMed ID: 24346129
    [No Abstract]   [Full Text] [Related]  

  • 18. Correlation of Methylated Circulating Tumor DNA With Response to Neoadjuvant Chemotherapy in Breast Cancer Patients.
    Takahashi H; Kagara N; Tanei T; Naoi Y; Shimoda M; Shimomura A; Shimazu K; Kim SJ; Noguchi S
    Clin Breast Cancer; 2017 Feb; 17(1):61-69.e3. PubMed ID: 27395416
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of TP53/PIK3CA Mutations in Cell-Free Plasma DNA From Metastatic Breast Cancer Patients Using Next Generation Sequencing.
    Nakauchi C; Kagara N; Shimazu K; Shimomura A; Naoi Y; Shimoda M; Kim SJ; Noguchi S
    Clin Breast Cancer; 2016 Oct; 16(5):418-423. PubMed ID: 27265061
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of cell free DNA in breast oncology.
    Canzoniero JV; Park BH
    Biochim Biophys Acta; 2016 Apr; 1865(2):266-74. PubMed ID: 27012505
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.